TDMS Study 05044-01 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
4-VINYL-1-CYCLOHEXENE DIEPOXIDE
NTP Experiment-Test: 05044-01 Report: PEIRPT05
Study Type: CHRONIC Date: 09/06/94
Route: DERMAL,SOLUTION Time: 10:15:45
Facility: Battelle Columbus Laboratory
Chemical CAS #: 106-87-6
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05044-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 10:15:45
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60
Scheduled Sacrifice 10 10 10
Early Deaths
Dead 8 13 21
Moribund 15 14 14
Survivors
Terminal Sacrifice 27 23 15
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Liver (50) (50) (50)
Neoplastic Nodule 1 (2%)
Mesentery (4) (2)
Lipoma 1 (50%)
Pancreas (48) (47) (48)
Pharynx (1) (1)
Palate, Squamous Cell Carcinoma 1 (100%)
Stomach, Forestomach (50) (48) (50)
Stomach, Glandular (50) (48) (50)
Tongue (1) (1) (1)
Squamous Cell Papilloma 1 (100%) 1 (100%) 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (50) (48) (50)
Adenoma 1 (2%) 1 (2%)
Adrenal Gland, Medulla (50) (48) (50)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 2 (4%) 2 (4%) 1 (2%)
Bilateral, Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (48) (48) (48)
Adenoma 1 (2%) 1 (2%)
Parathyroid Gland (47) (43) (48)
Adenoma 1 (2%) 1 (2%)
Pituitary Gland (47) (49) (48)
Page 2
NTP Experiment-Test: 05044-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 10:15:45
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
Pars Distalis, Adenoma 19 (40%) 14 (29%) 17 (35%)
Pars Distalis, Carcinoma 14 (30%) 15 (31%) 11 (23%)
Thyroid Gland (46) (48) (49)
Bilateral, C-Cell, Adenoma 1 (2%) 2 (4%)
C-Cell, Adenoma 4 (9%) 12 (25%) 9 (18%)
C-Cell, Adenoma, Multiple 1 (2%)
C-Cell, Carcinoma 3 (6%) 1 (2%)
Follicular Cell, Adenoma 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (45) (50) (49)
Adenoma 2 (4%) 7 (14%) 3 (6%)
Carcinoma 1 (2%)
Sarcoma 1 (2%)
Ovary (50) (49) (50)
Granulosa Cell Tumor Benign 1 (2%)
Luteoma 1 (2%)
Uterus (50) (50) (50)
Carcinoma 1 (2%)
Polyp Stromal 3 (6%) 7 (14%) 6 (12%)
Polyp Stromal, Multiple 1 (2%)
Sarcoma Stromal 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Blood (3) (1)
Bone Marrow (50) (49) (49)
Lymph Node (50) (50) (50)
Axillary, Squamous Cell Carcinoma,
Metastatic, Skin 1 (2%)
Lymph Node, Mandibular (50) (50) (50)
Lymph Node, Mesenteric (3) (2)
Hemangiosarcoma 1 (50%)
Spleen (50) (50) (49)
Thymus (44) (43) (41)
Thymoma Benign 1 (2%)
Thymoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 05044-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 10:15:45
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (49) (50)
Adenocarcinoma 2 (4%) 3 (6%) 1 (2%)
Fibroadenoma 14 (28%) 11 (22%) 8 (16%)
Fibroadenoma, Multiple 6 (12%)
Skin (50) (50) (50)
Basal Cell Adenoma 1 (2%) 1 (2%)
Back, Squamous Cell Carcinoma 1 (2%)
Back, Sebaceous Gland, Adenoma 1 (2%)
Scapula, Basal Cell Carcinoma 3 (6%) 4 (8%)
Scapula, Squamous Cell Carcinoma 8 (16%) 12 (24%)
Scapula, Squamous Cell Carcinoma, Multiple 8 (16%) 22 (44%)
Scapula, Squamous Cell Papilloma 1 (2%)
Sebaceous Gland, Scapula, Adenoma 1 (2%) 1 (2%)
Subcutaneous Tissue, Fibroma 2 (4%)
Subcutaneous Tissue, Lipoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1)
Abdominal, Rhabdomyosarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50)
Carcinoma, Metastatic, Pituitary Gland 3 (6%) 3 (6%) 3 (6%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50)
Squamous Cell Carcinoma, Metastatic, Skin 3 (6%)
Nose (49) (50) (49)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05044-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 10:15:45
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (49)
Nephroblastoma Malignant 1 (2%)
Urinary Bladder (50) (50) (48)
Transitional Epithelium, Papilloma 2 (4%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Leukemia Mononuclear 12 (24%) 17 (34%) 13 (26%)
Lymphoma Malignant Histiocytic 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05044-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 10:15:45
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 43 47 44
Total Primary Neoplasms 95 128 119
Total Animals with Benign Neoplasms 39 40 32
Total Benign Neoplasms 62 67 52
Total Animals with Malignant Neoplasms 25 38 39
Total Malignant Neoplasms 33 61 67
Total Animals with Metastatic Neoplasms 3 3 6
Total Metastatic Neoplasm 3 3 7
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05044-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 10:15:45
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60
Scheduled Sacrifice 10 10 10
Early Deaths
Moribund 31 37 29
Dead 12 5 16
Drowned 1
Survivors
Terminal Sacrifice 7 8 4
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (45) (48) (40)
Intestine Large, Colon (48) (49) (40)
Carcinoma 1 (2%)
Intestine Large, Rectum (48) (48) (44)
Carcinoma 1 (2%)
Intestine Small, Duodenum (48) (50) (45)
Adenocarcinoma 1 (2%)
Intestine Small, Ileum (44) (49) (37)
Intestine Small, Jejunum (46) (49) (42)
Liver (50) (50) (50)
Carcinoma, Metastatic, Islets, Pancreatic 1 (2%)
Squamous Cell Carcinoma, Metastatic, Skin 1 (2%)
Mesentery (7) (6) (6)
Carcinoma, Metastatic, Skin 1 (17%)
Carcinoma, Metastatic, Intestine Large 1 (17%)
Squamous Cell Carcinoma, Metastatic, Skin 1 (17%)
Pancreas (50) (50) (45)
Carcinoma, Metastatic, Intestine Large 1 (2%)
Squamous Cell Carcinoma, Metastatic, Skin 1 (2%)
Pharynx (2) (2)
Palate, Squamous Cell Papilloma 1 (50%)
Salivary Glands (50) (50) (50)
Carcinoma, Metastatic, Skin 1 (2%)
Squamous Cell Carcinoma, Metastatic, Skin 1 (2%)
Stomach, Forestomach (50) (50) (47)
Stomach, Glandular (50) (50) (48)
Leiomyosarcoma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Skin 1 (2%)
Tongue (1) (1)
Squamous Cell Papilloma 1 (100%)
Page 7
NTP Experiment-Test: 05044-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 10:15:45
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50)
Carcinoma, Metastatic, Skin 1 (2%)
Squamous Cell Carcinoma, Metastatic, Skin 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (50) (50) (50)
Medulla, Squamous Cell Carcinoma, Metastatic,
Skin 1 (2%)
Adrenal Gland, Medulla (50) (50) (50)
Pheochromocytoma Malignant 2 (4%)
Pheochromocytoma Benign 6 (12%) 11 (22%)
Bilateral, Pheochromocytoma Benign 2 (4%) 4 (8%)
Islets, Pancreatic (50) (50) (46)
Adenoma 1 (2%) 2 (4%) 3 (7%)
Carcinoma 2 (4%)
Parathyroid Gland (49) (45) (45)
Adenoma 2 (4%) 1 (2%)
Pituitary Gland (50) (50) (48)
Pars Distalis, Adenoma 24 (48%) 26 (52%) 26 (54%)
Pars Distalis, Adenoma, Multiple 1 (2%)
Pars Distalis, Carcinoma 2 (4%) 1 (2%)
Thyroid Gland (48) (50) (43)
C-Cell, Adenoma 7 (15%) 5 (10%) 2 (5%)
C-Cell, Adenoma, Multiple 1 (2%)
C-Cell, Carcinoma 2 (4%)
Follicular Cell, Adenoma 1 (2%) 3 (6%) 3 (7%)
Follicular Cell, Carcinoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (48)
Preputial Gland (49) (49) (50)
Adenoma 3 (6%) 1 (2%)
Squamous Cell Papilloma 2 (4%)
Prostate (49) (50) (50)
Testes (50) (50) (50)
Page 8
NTP Experiment-Test: 05044-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 10:15:45
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Bilateral, Interstitial Cell, Adenoma 34 (68%) 35 (70%) 25 (50%)
Interstitial Cell, Adenoma 10 (20%) 5 (10%) 14 (28%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Blood (7) (1) (2)
Bone Marrow (50) (50) (49)
Femoral, Squamous Cell Carcinoma, Metastatic,
Skin 1 (2%)
Lymph Node (50) (50) (50)
Mediastinal, Carcinoma, Metastatic, Skin 1 (2%)
Lymph Node, Mandibular (50) (49) (50)
Lymph Node, Mesenteric (7) (10) (3)
Carcinoma, Metastatic, Intestine Large 1 (10%)
Mediastinal, Squamous Cell Carcinoma,
Metastatic, Skin 1 (10%)
Spleen (50) (50) (49)
Squamous Cell Carcinoma, Metastatic, Skin 1 (2%)
Thymus (41) (40) (42)
Thymoma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (45) (48) (42)
Adenocarcinoma 1 (2%) 2 (4%)
Fibroadenoma 1 (2%) 1 (2%) 1 (2%)
Skin (50) (50) (50)
Basal Cell Adenoma 1 (2%)
Basal Cell Carcinoma 1 (2%) 1 (2%)
Keratoacanthoma 2 (4%)
Trichoepithelioma 1 (2%)
Back, Keratoacanthoma 1 (2%)
Back, Squamous Cell Carcinoma 2 (4%) 1 (2%)
Back, Subcutaneous Tissue, Fibroma 1 (2%)
Back, Sebaceous Gland, Adenoma 1 (2%)
Scapula, Basal Cell Adenoma 4 (8%)
Scapula, Basal Cell Carcinoma 1 (2%) 2 (4%)
Scapula, Basal Cell Carcinoma, Multiple 1 (2%)
Scapula, Basal Cell Carcinoma, Metastatic,
Skin 1 (2%)
Scapula, Carcinoma 1 (2%)
Scapula, Keratoacanthoma 1 (2%) 1 (2%)
Scapula, Squamous Cell Carcinoma 10 (20%) 12 (24%)
Scapula, Squamous Cell Carcinoma, Multiple 22 (44%) 24 (48%)
Scapula, Squamous Cell Carcinoma, Metastatic,
Page 9
NTP Experiment-Test: 05044-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 10:15:45
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - cont
Skin 1 (2%)
Scapula, Squamous Cell Papilloma 3 (6%) 6 (12%)
Sebaceous Gland, Scapula, Adenoma 1 (2%) 1 (2%)
Subcutaneous Tissue, Fibroma 1 (2%) 1 (2%)
Subcutaneous Tissue, Hemangioma 1 (2%)
Subcutaneous Tissue, Liposarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%)
Subcutaneous Tissue, Scapula, Fibrosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1) (1)
Diaphragm, Carcinoma, Metastatic, Skin 1 (100%)
Diaphragm, Intercostal, Squamous Cell
Carcinoma, Metastatic, Skin 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (49)
Carcinoma, Metastatic, Pituitary Gland 1 (2%)
Squamous Cell Carcinoma, Metastatic, Skin 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50)
Carcinoma, Metastatic 1 (2%)
Carcinoma, Metastatic, Skin 1 (2%)
Chordoma 1 (2%)
Pheochromocytoma Malignant, Metastatic,
Adrenal Gland 1 (2%)
Squamous Cell Carcinoma, Metastatic, Skin 4 (8%) 1 (2%)
Squamous Cell Carcinoma, Metastatic,
Uncertain Primary Site 1 (2%)
Nose (50) (50) (49)
Trachea (50) (49) (48)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (7) (3) (6)
Zymbal's Gland (2)
Adenoma 1 (50%)
Carcinoma 1 (50%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 05044-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 10:15:45
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (49)
Carcinoma, Metastatic, Skin 1 (2%)
Squamous Cell Carcinoma, Metastatic, Skin 1 (2%)
Renal Tubule, Adenoma 1 (2%)
Urinary Bladder (49) (50) (49)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Leukemia Mononuclear 16 (32%) 15 (30%) 15 (30%)
Mesothelioma Malignant 1 (2%) 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 11
NTP Experiment-Test: 05044-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 10:15:45
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 50 49 49
Total Primary Neoplasms 117 173 156
Total Animals with Benign Neoplasms 50 45 46
Total Benign Neoplasms 90 111 94
Total Animals with Malignant Neoplasms 24 39 41
Total Malignant Neoplasms 27 62 62
Total Animals with Metastatic Neoplasms 1 7 5
Total Metastatic Neoplasm 1 23 11
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 12
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------
--multipart-boundary
Content-type: text/plain
Range: bytes 70056-70056/70056
--multipart-boundary--